Research
Our main research is in the field of Gynecologic Oncology, with a special focus in understanding the interactions between cell signaling pathways implicated in ovarian cancer and endometrial cancer pathogenesis as a means to target therapy for this disease. We have pursued and investigated many novel therapies including:
- Akt/ERK inhibitors
- PD1/PDL1 inhibitors
- Cdk1 inhibitors
- Metformin and other biguanides
- mTOR inhibitors
- IGF-1R monoclonal antibodies
- Soy
- Genistein
- Arsenic
Our efforts have led to numerous completed and ongoing clinical trials in this field, including:
- LCCC 2036: A Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (PI) – opening Spring 2022
- LCCC2135: Impact of the Uterine and Gut Microbiomes in Endometrial Cancer Development and Treatment – opening Spring 2022
- NRG-GY028: A Phase IB and Randomized Phase II Trial of Medroxyprogesterone Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer (Translational Science Co-Chair) – opening Spring 2022
- SISTER: Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (Site PI) – ongoing
- LCCC 1855: MASCOT – Manufacturing and Analysis of Stem Cells from Skin Cells for Ovarian Cancer Treatment (PI) – ongoing
- LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients (PI) – ongoing
- Carolina Endometrial Cancer Study (CECS) (Co-Leader) – ongoing
- LCCC 1839: Pre-operative Window Study of Interval Exercise Training as a Therapy for Endometrial Cancer (PI) – ongoing
- LCCC1739: Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer (PI) – ongoing
- LCCC2054: Obesity, Frailty, and Age-Related Responses to Surgery and Treatment in Endometrial Cancer Patients (Mentor to gynecologic oncology fellow PI) – ongoing
- ONC012: A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer (site PI) – completed
- LCCC 1514: Evaluating the Anti-Proliferative Effects of Atorvastatin on the Endometrium of Endometrial Cancer Patients: A Pre-Operative Window Study (Mentor to gynecologic oncology fellow PI) – completed
- Gynecologic Oncology Associates: Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed with Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma (Translational PI) – completed
- GOG 286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer (PI) – completed
- LCCC 1205: Metformin for the Treatment of Endometrial Hyperplasia – completed
- LCCC 1102: Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer – completed
- LCCC 0828: A Molecular Pathway to Therapeutic Intervention and Individualized Treatment for Endometrial Cancer – completed
Affiliated Research Programs
The Carolina Endometrial Cancer Study (CECS)
Dr. Bae-Jump serves as an investigator on the CECS
CECS is a population-based study of endometrial cancer that is being conducted statewide in North Carolina in conjunction with the Central Cancer Registry. CECS seeks to address two major disparities in the treatment of endometrial cancer.
UNC TREND (Translational Research in Endometrial Cancer Disparities)
Dr. Bae-Jump is a joint leader for UNC TREND
UNC TREND is designed to promote translational, laboratory, population, and clinical research to reduce cancer disparities in Non-Hispanic Black women with endometrial cancer. Through two research focus projects, the UNC TREND team will investigate the impact of various factors on endometrial cancer outcomes.
UNC Lineberger Endometrial Cancer Center of Excellence
Dr. Bae-Jump is the director of the Endometrial Cancer Center of Excellence
The UNC Lineberger Endometrial Cancer Center of Excellence brings together an outstanding group of researchers, clinicians and staff to provide excellent multidisciplinary patient care and generate research discoveries that can be translated into new, more effective approaches and ultimately, cures for endometrial cancer.